Other languages Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Real-time Estimate Cboe BZX Other stock markets 09:55:00 20/06/2024 pm IST			5-day change	1st Jan Change
6.65 ^USD	+0.30%		-13.73%	+35.37%

14/05	Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	North American Morning Briefing : More Earnings -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress At Corporate R&D Event	25/04
Top Midday Gainers	09/04
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday on Caution Ahead of Inflation Data	09/04
Acrivon Therapeutics Announces Private Placement of 8.2 Million Shares; Shares Surge	09/04
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09/04
Top Premarket Gainers	09/04
Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Acrivon Therapeutics, Inc. Appoints Santhosh Palani to its Board of Directors	04/03
Acrivon Therapeutics, Inc. Appoints Ivana Magovcevic-Liebisch to its Board of Directors	08/02
Acrivon Therapeutics Names Jean-Marie Cuillerot as Chief Medical Officer	04/01
Acrivon Therapeutics, Inc. Announces Management Changes	03/01
Acrivon Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer	28/11
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Acrivon Therapeutics, Inc. Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon?s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies	06/23/06
Acrivon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Acrivon Therapeutics Announces the Appointment of Adam Levy as Senior Vice President and Head, Investor Relations and Corporate Affairs	20/23/20
Acrivon Therapeutics, Inc. Appoints Charles Baum as Board of Directors	23/23/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Other languages

Filters